Oryon Cell Therapies Emerges From Stealth With $21 Million Series A
2026-03-23
Tweet
BELMONT, MA, Oryon Cell Therapies, a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing its total funding in equity and grants to $42 million.
Oryon Cell Therapies, a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing its total funding in equity and grants to $42 million. Investors included Neuro.VC, Byers Capital, and others. The company's initial program is a neuron replacement therapy designed to restore dopaminergic function in the brains of people with Parkinson's disease.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
